Neurocrine Biosciences, Inc. (NBIX) Q1 2017 Earnings Results

Neurocrine Biosciences Misses on EPS, Stock Up 1.82%

Neurocrine Biosciences reported a larger-than-expected loss per share, which typically raises concerns among investors. However, the stock rose by 1.82%, likely driven by management's positive outlook on their pipeline and long-term strategy. Investors may be encouraged by the focus on future growth despite the current financial setback.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.90	N/A	-24.31%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Management expressed cautious optimism about future developments. They highlighted ongoing efforts to enhance their product pipeline and remain focused on long-term goals.

Management acknowledged the challenges faced in the quarter.

They emphasized their commitment to advancing their pipeline.

There was a focus on long-term growth despite the current EPS miss.

Neurocrine Biosciences Misses on EPS, Stock Up 1.82%

Key numbers

Management commentary

Neurocrine Biosciences, Inc.

More earnings this week

Neurocrine Biosciences Misses on EPS, Stock Up 1.82%

Key numbers

Management commentary